-
摘要: 间接药物性肝毒性(IDLT)指一些药物的使用可诱发新的肝脏疾病或加重原有肝病病情,表型是那些潜在的肝脏疾病或易患病。IDLT可导致持续性肝损伤甚至急性肝衰竭,还可影响肿瘤或其他共存疾病的药物治疗,导致正在进行的化疗、免疫和靶向治疗暂停或终止,应引起重视和识别。本文针对几种IDLT机制及防治策略进行了阐述。
-
关键词:
- 化学性与药物性肝损伤 /
- 间接肝毒性 /
- 治疗学
Abstract: Indirect drug-induced liver toxicity (IDLT) refers to the condition that the use of some therapeutic drugs may induce new liver diseases or exacerbate the original liver disease, with the phenotype of underlying or predisposed liver diseases. IDLT may induce persistent liver injury or even acute liver failure and affect the pharmacotherapy for tumor or other comorbidities, leading to the suspension or termination of ongoing chemotherapy, immunotherapy, and targeted therapy, and therefore, it should be taken seriously in clinical practice. This article elaborates on the mechanisms and prevention strategies of several types of IDLT. -
[1] HOOFNAGLE JH, EINAR S, BJ RNSSON ES. Drug-induced liver injury-types and phenotypes[J]. N Engl J Med, 2019, 381(3): 264-273. DOI: 10.1056/NEJMra1816149. [2] ANDRADE RJ, AITHAL GP, BJÖRNSSON ES, et al. EASL clinical practice guidelines: drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261. DOI: 10.1016/j.jhep.2019.02.014. [3] CHALASANI NP, MADDUR H, RUSSO MW, et al. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116(5): 878-898. DOI: 10.14309/ajg.0000000000001259. [4] YU YC, MAO YM, CHEN CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int, 2017, 11(3): 221-241. DOI: 10.1007/s12072-017-9793-2. [5] LOOMBA R, LIANG TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions[J]. Gastroenterology, 2017, 152: 1297-1309. DOI: 10.1053/j.gastro.2017.02.009. [6] EKPANYAPONG S, REDDY KR. Hepatitis B virus reactivation: What is the issue, and how should it be managed?[J]. Clin Liver Dis, 2020, 24(3): 317-333. DOI: 10.1016/j.cld.2020.04.002. [7] YAO ZH, LIAO WY, HO CC, et al. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients[J]. Eur J Cancer, 2019, 117: 107-115. DOI: 10.1016/j.ejca.2019.05.032. [8] BURNS EA, MUHSEN IN, ANAND K, et al. Hepatitis B virus reactivation in cancer patients treated with immune checkpoint inhibitors[J]. J Immunother, 2021, 44(3): 132-139. DOI: 10.1097/cji.0000000000000358. [9] ZHANG X, ZHOU Y, CHEN C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition[J]. J Immunother Cancer, 2019, 7(1): 322. DOI: 10.1186/s40425-019-0808-5. [10] LEE PC, CHAO Y, CHEN MH, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(2): e001072. DOI: 10.1136/jitc-2020-001072. [11] YAU T, HSU C, KIM TY, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis[J]. J Hepatol, 2019, 71(3): 543-552. DOI: 10.1016/j.jhep.2019.05.014. [12] KOKSAL AS, TOKA B, EMINLER AT, et al. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma[J]. Ann Oncol, 2017, 28(12): 3103-3104. DOI: 10.1093/annonc/mdx502. [13] GODBERT B, PETITPAIN N, LOPEZ A, et al. Hepatitis B reactivation and immune check point inhibitors[J]. Dig Liver Dis, 2021, 53(4): 452-455. DOI: 10.1016/j.dld.2020.08.041. [14] PEERAPHATDIT TB, WANG J, ODENWALD MA, et al. Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation[J]. Hepatology, 2020, 72(1): 315-329. DOI: 10.1002/hep.31227. [15] JENNINGS JJ, MANDALIYA R, NAKSHABANDI A, et al. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies[J]. Expert Opin Drug Metab Toxicol, 2019, 15(3): 231-244. DOI: 10.1080/17425255.2019.1574744. [16] WANG W, LIE P, GUO M, et al. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data[J]. Int J Cancer, 2017, 141(5): 1018-1028. DOI: 10.1002/ijc.30678. [17] SUZMAN DL, PELOSOF L, ROSENBERG A, et al. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents[J]. Liver Int, 2018, 38(6): 976-987. DOI: 10.1111/liv.13746. [18] SANJEEVAIAH A, KERR T, BEG MS. Approach and management of checkpoint inhibitor-related immune hepatitis[J]. J Gastrointest Oncol, 2018, 9(1): 220-224. DOI: 10.21037/jgo.2017.08.14. [19] GROVER S, RAHMA OE, HASHEMI N, et al. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management[J]. Am Soc Clin Oncol Educ Book, 2018, 38: 13-19. DOI: 10.1200/EDBK_100013. [20] ALLARD J, LE GUILLOU D, BEGRICHE K, et al. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease[J]. Adv Pharmacol, 2019, 85: 75-107. DOI: 10.1016/bs.apha.2019.01.003. [21] Tamoxifen. LiverTox: Clinical and research information on drug-induced liver injury[M/OL]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012. [22] CATALDI M, CITRO V, RESNATI C, et al. New avenues for treatment and prevention of drug-induced steatosis and steatohepatitis: Much more than antioxidants[J]. Adv Ther, 2021, 38(5): 2094-2113. DOI: 10.1007/s12325-021-01669-y.
本文二维码
计量
- 文章访问数: 337
- HTML全文浏览量: 110
- PDF下载量: 66
- 被引次数: 0